CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 158 enrolled
Drug / intervention
Reproxalap Ophthalmic Solution (0.25%) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04971031
NCT04971031Phase 2Completed
CompareCT.gov

A Multi-Center Randomized, Double-Masked, Parallel Design, Vehicle-Controlled Phase 2 Clinical Trial to Assess the Efficacy and Safety of 0.25% Reproxalap Ophthalmic Solution Compared to Vehicle in Subjects With Dry Eye Disease

Aldeyra Therapeutics, Inc.·interventional·Posted Jul 21, 2021·Updated Feb 24, 2025

In Brief

A Phase 2 clinical trial evaluating Reproxalap Ophthalmic Solution (0.25%) and Vehicle Ophthalmic Solution for Dry Eye. Completed, enrolled 158 participants across 1 site.

Detailed Summary

A Multi-Center Randomized, Double-Masked, Parallel Design, Vehicle-Controlled Phase 2 Clinical Trial to Assess the Efficacy and Safety of 0.25% Reproxalap Ophthalmic Solution Compared to Vehicle in Subjects with Dry Eye Disease

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDry Eye
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20222023202420252026
First PostedJul 21, 2021
Enrollment StartJun 15, 2021
Primary CompletionSep 8, 2021
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 4.9 years ago

Interventions

Reproxalap Ophthalmic Solution (0.25%)drug

Reproxalap Ophthalmic Solution (0.25%) administered 7 times over two consecutive days.

Vehicle Ophthalmic Solutiondrug

Vehicle Ophthalmic Solution administered 7 times over two consecutive days.